IMMUNITYBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.81 USD | -14.64% |
|
-13.13% | +55.58% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,419 | 2,076 | 3,352 | 5,287 | - | - |
| Enterprise Value (EV) 1 | 2,419 | 2,076 | 3,352 | 5,287 | 5,287 | 5,287 |
| P/E ratio | -6.83 x | -4.88 x | -4.37 x | -10.5 x | -15 x | -50.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2,590 x | 8,648 x | 5,389 x | 73.9 x | 19.1 x | 10.1 x |
| EV / Revenue | 2,590 x | 8,648 x | 5,389 x | 73.9 x | 19.1 x | 10.1 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -7.85 x | -4.99 x | - | -17.1 x | -29.2 x | 96.1 x |
| FCF Yield | -12.7% | -20% | - | -5.86% | -3.42% | 1.04% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 397,800 | 409,395 | 667,705 | 677,003 | - | - |
| Reference price 2 | 6.080 | 5.070 | 5.020 | 7.810 | 7.810 | 7.810 |
| Announcement Date | 3/1/22 | 3/1/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.934 | 0.24 | 0.622 | 71.56 | 277.4 | 521.2 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -330.3 | -351.3 | -362.2 | -331.8 | -187.5 | 4.976 |
| Operating Margin | -35,361.88% | -146,374.17% | -58,239.55% | -463.68% | -67.6% | 0.95% |
| Earnings before Tax (EBT) 1 | -349.8 | -417.3 | -583.9 | -439.1 | -308.2 | -81.22 |
| Net income 1 | -346.8 | -416.6 | -583.2 | -436.9 | -306.5 | -80.27 |
| Net margin | -37,129.55% | -173,569.58% | -93,761.41% | -610.53% | -110.5% | -15.4% |
| EPS 2 | -0.8900 | -1.040 | -1.150 | -0.7450 | -0.5200 | -0.1550 |
| Free Cash Flow 1 | -308 | -415.7 | - | -310 | -181 | 55 |
| FCF margin | -32,974.52% | -173,196.25% | - | -433.22% | -65.25% | 10.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 3/1/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.066 | 0.39 | 0.014 | 0.035 | 0.118 | 0.073 | 0.36 | 0.041 | 0.082 | 0.139 | 0.025 | 2.525 | 10.02 | 22.74 | 35.02 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -78.84 | -79.27 | -95.97 | - | -90.8 | -84.9 | -111.6 | -85.14 | -80.14 | -85.39 | -87.48 | -90.91 | -85.72 | -78.68 | -68.6 |
| Operating Margin | -119,448.48% | -20,326.67% | -685,514.29% | - | -76,952.54% | -116,301.37% | -30,994.44% | -207,670.73% | -97,726.83% | -61,430.94% | -349,900% | -3,600.51% | -855.11% | -346.03% | -195.86% |
| Earnings before Tax (EBT) 1 | -88.43 | -91.55 | -103 | - | -111.2 | -108.3 | -116.6 | -138.2 | -95.64 | -233.5 | -110.8 | -114.6 | -109.4 | -102.7 | -92.99 |
| Net income 1 | -88.43 | -91.26 | -102.8 | - | -110.9 | -108.2 | -116.3 | -137.9 | -95.58 | -233.4 | -110.8 | -114.6 | -109.4 | -102.7 | -92.99 |
| Net margin | -133,983.33% | -23,399.74% | -734,471.43% | - | -94,015.25% | -148,239.73% | -32,317.5% | -336,290.24% | -116,563.41% | -167,907.91% | -443,088% | -4,539.29% | -1,090.81% | -451.7% | -265.49% |
| EPS 2 | -0.2200 | -0.2300 | -0.2600 | -0.2400 | -0.2800 | -0.2700 | -0.2700 | -0.3200 | -0.1900 | -0.3800 | -0.1600 | -0.1700 | -0.1600 | -0.1500 | -0.1400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/1/22 | 5/10/22 | 8/8/22 | 11/9/22 | 3/1/23 | 5/11/23 | 8/8/23 | 11/9/23 | 3/19/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -308 | -416 | - | -310 | -181 | 55 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 78.2 | - | - | - | - |
| Capex / Sales | - | 32,567.5% | - | - | - | - |
| Announcement Date | 3/1/22 | 3/1/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.81
USD
Average target price
7.5
USD
Spread / Average Target
-3.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.58% | 5.29B | |
| +9.15% | 106B | |
| -1.08% | 104B | |
| +6.17% | 23.25B | |
| -11.55% | 22.5B | |
| -6.59% | 18.7B | |
| -37.08% | 17.95B | |
| -9.91% | 16.99B | |
| +7.55% | 14.26B | |
| +40.04% | 12.76B |
- Stock Market
- Equities
- IBRX Stock
- Financials ImmunityBio, Inc.